XNAS 27 Apr, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| John C.M. Farquhar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.72 per share. | 10 Apr 2026 | 22,562 | 549,163 | - | 26.7 | 602,857 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.33 per share. | 01 Apr 2026 | 291 | 78,809 | - | 8.3 | 2,424 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 40,766 | 81,633 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 19,111 | 122,399 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 291 | 3,298 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 6,849 | 0 | - | - | Stock Options | |
| Campbell D.K. Rogers | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.64 per share. | 01 Apr 2026 | 64,533 | 81,002 | - | 24.6 | 1,590,093 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 01 Apr 2026 | 6,849 | 145,535 | - | 2.2 | 15,205 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 01 Apr 2026 | 40,766 | 138,686 | - | 2.2 | 90,501 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 01 Apr 2026 | 19,111 | 97,920 | - | 2.2 | 42,426 | Common Stock |
| Jeffrey C. Lightcap | Director | Other type of transaction at price $ 0.00 per share. | 24 Mar 2026 | 206,261 | 246,261 | - | 0 | Common Stock | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 19 Mar 2026 | 19,402 | 95,436 | - | 2.2 | 43,072 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2026 | 47,615 | 141,510 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2026 | 19,402 | 189,125 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.69 per share. | 19 Mar 2026 | 64,533 | 78,518 | - | 25.7 | 1,658,033 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 19 Mar 2026 | 47,615 | 143,051 | - | 2.2 | 105,705 | Common Stock |
| John C.M. Farquhar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 18 Mar 2026 | 9,725 | 571,725 | - | 25 | 243,125 | Common Stock |
| Timothy C. Barabe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 11 Mar 2026 | 8,667 | 179,521 | - | 2.2 | 19,241 | Common Stock |
| Timothy C. Barabe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2026 | 8,667 | 15,412 | - | - | Stock Option | |
| John C.M. Farquhar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.66 per share. | 10 Mar 2026 | 12,837 | 581,450 | - | 22.7 | 290,886 | Common Stock |
| John C.M. Farquhar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 16.15 per share. | 10 Mar 2026 | 2,631 | 594,287 | - | 16.2 | 42,491 | Common Stock |
| Julie Anne Cullivan | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 05 Mar 2026 | 9,122 | 27,291 | - | 25 | 228,050 | Common Stock |
| Timothy C. Barabe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.33 per share. | 17 Feb 2026 | 2,497 | 170,854 | - | 8.3 | 20,800 | Common Stock |
| Timothy C. Barabe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 2,497 | 0 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.49 per share. | 12 Feb 2026 | 65,153 | 76,034 | - | 24.5 | 1,595,486 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 7,906 | 208,527 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 19,401 | 216,433 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 39,709 | 0 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 12 Feb 2026 | 19,401 | 93,572 | - | 2.2 | 43,070 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.33 per share. | 12 Feb 2026 | 39,709 | 133,281 | - | 8.3 | 330,776 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.22 per share. | 12 Feb 2026 | 7,906 | 141,187 | - | 2.2 | 17,551 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 94,488 | 94,488 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.74 per share. | 06 Feb 2026 | 515 | 20,098 | - | 27.7 | 14,286 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 54,073 | 74,171 | - | 0 | Common Stock | |
| John C.M. Farquhar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 321,259 | 321,259 | - | - | Stock Option | |
| John C.M. Farquhar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.74 per share. | 06 Feb 2026 | 1,541 | 430,368 | - | 27.7 | 42,747 | Common Stock |
| John C.M. Farquhar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 183,850 | 614,218 | - | 0 | Common Stock | |
| John C.M. Farquhar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.46 per share. | 06 Feb 2026 | 22,562 | 591,656 | - | 27.5 | 619,553 | Common Stock |
| Vikram Verghese | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 119,685 | 119,685 | - | - | Stock Option | |
| Vikram Verghese | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 68,493 | 212,863 | - | 0 | Common Stock. | |
| Vikram Verghese | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.74 per share. | 06 Feb 2026 | 542 | 144,370 | - | 27.7 | 15,035 | Common Stock. |
| Mhairi L. Jones | Chief Accounting Officer, VP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.74 per share. | 06 Feb 2026 | 94 | 10,021 | - | 27.7 | 2,608 | Common Stock. |
| Mhairi L. Jones | Chief Accounting Officer, VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 21,629 | 31,650 | - | 0 | Common Stock. | |
| Mhairi L. Jones | Chief Accounting Officer, VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 37,795 | 37,795 | - | - | Stock Option | |
| Julie Anne Cullivan | Director | Sale of securities on an exchange or to another person at price $ 27.32 per share. | 05 Feb 2026 | 8,000 | 36,413 | - | 27.3 | 218,560 | Common Stock |
| Jeffrey C. Lightcap | Director | Purchase of securities on an exchange or from another person at price $ 26.34 per share. | 16 Dec 2025 | 40,000 | 40,000 | - | 26.3 | 1,053,680 | Common Stock |
| Campbell D.K. Rogers | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.56 per share. | 07 Nov 2025 | 439 | 20,613 | - | 32.6 | 14,294 | Common Stock |
| John C.M. Farquhar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.56 per share. | 07 Nov 2025 | 1,339 | 431,909 | - | 32.6 | 43,598 | Common Stock |
| Vikram Verghese | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.56 per share. | 07 Nov 2025 | 471 | 144,912 | - | 32.6 | 15,336 | Common Stock. |
| Mhairi L. Jones | Chief Accounting Officer, VP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.56 per share. | 07 Nov 2025 | 81 | 10,115 | - | 32.6 | 2,637 | Common Stock. |
| William C Weldon | Director | 07 Aug 2025 | 136,286 | 192,562 | - | - | Common Stock | ||
| William C Weldon | Director | 07 Aug 2025 | 27,704 | 0 | - | - | Series F-1 Preferred Stock | ||
| William C Weldon | Director | 07 Aug 2025 | 25,160 | 0 | - | - | Series F Preferred Stock | ||
| William C Weldon | Director | 07 Aug 2025 | 83,442 | 0 | - | - | Series D Preferred Stock | ||
| William C Weldon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 23,710 | 23,710 | - | - | Stock Option | |
| Timothy C. Barabe | Director | 07 Aug 2025 | 131,578 | 0 | - | - | Convertible Promissory Note | ||
| Timothy C. Barabe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 23,710 | 23,710 | - | - | Stock Option | |
| Timothy C. Barabe | Director | 07 Aug 2025 | 131,578 | 168,357 | - | - | Common Stock | ||
| Wayne Joseph Riley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 23,710 | 23,710 | - | - | Stock Option | |
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 833,075 | 833,075 | - | - | Common Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 1,248,939 | 1,248,939 | - | - | Common Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 4,615,542 | 4,615,542 | - | - | Common Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 624,471 | 0 | - | - | Series C Preferred Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 1,248,939 | 0 | - | - | Series C Preferred Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 1,630,231 | 0 | - | - | Series D Preferred Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 208,604 | 0 | - | - | Series D Preferred Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 1,099,378 | 0 | - | - | Series E Preferred Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 1,337,337 | 0 | - | - | Series F Preferred Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 452,528 | 0 | - | - | Series F-1 Preferred Stock | ||
| Jeffrey C. Lightcap | Director | 07 Aug 2025 | 96,068 | 0 | - | - | Convertible Promissory Note | ||
| Jeffrey C. Lightcap | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 47,420 | 47,420 | - | - | Stock Option | |
| Campbell D.K. Rogers | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 110,629 | 110,629 | - | - | Stock Options | |
| Campbell D.K. Rogers | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 21,052 | 21,052 | - | 0 | Common Stock | |
| Casey M. Tansey | Director | 07 Aug 2025 | 21,295 | 0 | - | - | Series C Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 10,106 | 0 | - | - | Series D Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 80,855 | 0 | - | - | Series D Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 323 | 0 | - | - | Series D Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 2,586 | 0 | - | - | Series D Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 1,164,179 | 0 | - | - | Series F Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 37,244 | 0 | - | - | Series F Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 51,736 | 0 | - | - | Convertible Promissory Note | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 1,655 | 0 | - | - | Convertible Promissory Note | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 16,447 | 0 | - | - | Convertible Promissory Note | ||
| Casey M. Tansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 47,420 | 47,420 | - | - | Stock Option | |
| Casey M. Tansey | Director | 07 Aug 2025 | 330,078 | 0 | - | - | Series B-1 Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 665,623 | 0 | - | - | Series C Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 3,072,759 | 3,072,759 | - | - | Common Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 98,303 | 98,303 | - | - | Common Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 16,447 | 16,447 | - | - | Common Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 220,052 | 0 | - | - | Series B-1 Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 10,560 | 0 | - | - | Series B-1 Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 7,040 | 0 | - | - | Series B-1 Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 220,052 | 0 | - | - | Series B-2 Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 330,078 | 0 | - | - | Series B-2 Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 10,560 | 0 | - | - | Series B-2 Preferred Stock | ||
| Casey M. Tansey | Director | 07 Aug 2025 | 7,040 | 0 | - | - | Series B-2 Preferred Stock | ||
| Julie Anne Cullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 23,710 | 23,710 | - | - | Stock Option | |
| John C.M. Farquhar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 314,603 | 314,603 | - | - | Stock Option | |
| John C.M. Farquhar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 59,868 | 433,248 | - | 0 | Common Stock | |
| Vikram Verghese | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 21,052 | 135,867 | - | 0 | Common Stock | |
| Vikram Verghese | Chief Financial Officer | 07 Aug 2025 | 9,516 | 0 | - | - | Convertible Promissory Note | ||
| Vikram Verghese | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 110,629 | 110,629 | - | - | Stock Option | |
| Vikram Verghese | Chief Financial Officer | 07 Aug 2025 | 9,516 | 145,383 | - | - | Common Stock. | ||
| Mhairi L. Jones | Chief Accounting Officer, VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 19,014 | 19,014 | - | - | Stock Option | |
| Mhairi L. Jones | Chief Accounting Officer, VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 3,618 | 3,618 | - | 0 | Common Stock | |
| Mhairi L. Jones | Chief Accounting Officer, VP | 07 Aug 2025 | 6,578 | 10,196 | - | - | Common Stock. | ||
| Mhairi L. Jones | Chief Accounting Officer, VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 68,492 | 68,492 | - | - | Stock Option | |
| Mhairi L. Jones | Chief Accounting Officer, VP | 07 Aug 2025 | 6,578 | 0 | - | - | Convertible Promissory Note |